Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Galanthamine

B Fulton1, P Benfield

  • 1Adis International Limited, Auckland, New Zealand.

Drugs & Aging
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Galanthamine, an acetylcholinesterase inhibitor, shows promise for Alzheimer's disease treatment by improving cognitive function in animal models and preliminary patient studies. Common side effects include nausea and vomiting, with no liver toxicity reported.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Moclobemide: An update of its pharmacological properties and therapeutic use.

Drugs·2017
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Participation by women in behavior analysis.

The Behavior analyst·2012
Same author

Social problem-solving interventions in medium secure settings for women.

Medicine, science, and the law·2011
Same author

Outcome of children requiring intensive care following haematopoietic SCT for primary immunodeficiency and other non-malignant disorders.

Bone marrow transplantation·2011
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
Same journal

Adapting the Geriatric Medicine 5Ms Framework to Geriatric Dermatology.

Drugs & aging·2026
Same journal

External Validation of a Community Pharmacy-Based Screening Tool for Frailty That Uses Routinely Collected Data.

Drugs & aging·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Galanthamine is a selective acetylcholinesterase inhibitor.
  • It has demonstrated potential in treating Alzheimer's disease.

Purpose of the Study:

  • To evaluate the efficacy and safety of galanthamine for Alzheimer's disease treatment.

Main Methods:

  • Assessed galanthamine's selectivity for acetylcholinesterase over butyrylcholinesterase.
  • Examined cognitive deficits in animal models.
  • Reviewed preliminary clinical data in Alzheimer's patients.

Main Results:

  • Galanthamine inhibits acetylcholinesterase more potently in erythrocytes than in brain tissue.
  • It attenuated cognitive deficits in animal models of learning and memory.
  • Preliminary patient data suggest a reduction in cognitive deterioration.

    • Conclusions:

    • Galanthamine exhibits potential as a therapeutic agent for Alzheimer's disease.
    • Nausea and vomiting are the primary adverse effects; liver toxicity was not observed.